ClinicalTrials.Veeva

Menu

Gluten Challenge in Celiac Disease - Which Formulation of Gluten Gives the Best Response? (SHAKE)

University of Oslo (UIO) logo

University of Oslo (UIO)

Status

Not yet enrolling

Conditions

Celiac Disease

Treatments

Dietary Supplement: Vital wheat gluten

Study type

Interventional

Funder types

Other

Identifiers

NCT07039773
24/27476

Details and patient eligibility

About

The goal of this clinical trial is to evaluate the immune response to gluten in patients with celiac disease (CeD) by comparing different forms of gluten administration. The participant population includes adults diagnosed with CeD, who are adhering to a gluten-free diet (GFD). The main questions it aims to answer are:

  • Does liquid gluten administration elicit a higher IL-2 cytokine response compared to solid gluten administration?
  • What is the relationship between serum IL-2 levels and gluten peptide serum concentrations following gluten challenges?

Researchers will compare the responses of two groups: participants receiving liquid gluten (shake) to those receiving solid gluten (cookie) to determine if there is a significant difference in the IL-2 response rates between the two forms.

Participants will be asked to:

  • Undergo two gluten challenges (liquid and solid) in a randomized order with at least 4 weeks apart.
  • Provide blood samples before and after each challenge to measure serum IL-2 levels and gluten peptide concentrations over a period of 6 hours.
  • Report any symptoms experienced following each gluten challenge.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • BMI 18-33 kg/m2
  • Willingness to comply with the study procedure and having signed informed, written consent
  • Previous diagnosis of coeliac disease according to established guidelines based on positive serology (Endomysium test, IgA-TG2 and/or IgG-DGP) (diagnosed in childhood) and a duodenal biopsy showing villous atrophy graded as Marsh 3 according to guidelines from European Society for Study of Coeliac Disease .
  • Strict adherence to a gluten-free diet at least the 12 last months.

Exclusion criteria

  • Positive serology (IgA-TG2 below upper level of normal) at screening visit
  • Pregnancy or breast feeding. Fertile women must use effective contraception.
  • Other inflammatory disease like uncontrolled hypothyreosis, type 1 diabetes, cardiovascular diseases, thyroid and renal disorders, inflammatory bowel diseases or any other disease that in the opinion of the responsible clinician makes the patient unsuitable for the study
  • Using of immunosuppressive/steroid medications
  • Wheat allergy
  • Severe acute infection

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

30 participants in 2 patient groups

Gluten shake
Active Comparator group
Description:
Liquid form
Treatment:
Dietary Supplement: Vital wheat gluten
Dietary Supplement: Vital wheat gluten
Gluten cookie
Active Comparator group
Description:
Solid form
Treatment:
Dietary Supplement: Vital wheat gluten
Dietary Supplement: Vital wheat gluten

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems